Michelle Man, OD
Optometrist · Chicago, ILNPI 1336528603
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Coopervision Inc. at 54.2% of the total. 2025 is the largest year on record at $7,638, 7.6 times the $1,007 reported in 2019. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $162.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$11K
- Visionary Optics LLC$3K
- Johnson & Johnson Vision Care, Inc.$1K
- Alcon$1K
- AbbVie$1K
- Rxsight Inc$822
- plus $2K from 13 others
What the payments were for
- Consulting fees$1,9009%
- Speaking & faculty fees$7,95039%
- Travel & lodging$3,27616%
- Food & beverage$4,94624%
- Gifts$2,27511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 31 | $11,019 |
| Visionary Optics LLC | 3 | $2,850 |
| Johnson & Johnson Vision Care, Inc. | 22 | $1,375 |
| Alcon | 18 | $1,255 |
| AbbVie(2 entities) | 9 | $1,105 |
| Rxsight Inc | 7 | $822 |
| Bausch & Lomb Americas Inc. | 9 | $532 |
| Sun Pharmaceutical Industries Inc. | 4 | $279 |
| Glaukos Corporation | 2 | $159 |
| Tarsus Pharmaceuticals, Inc. | 4 | $156 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $126 |
| Amgen | 1 | $124 |
| Kala Pharmaceuticals, Inc. | 1 | $123 |
| Oyster Point Pharma, Inc. | 5 | $119 |
| Shire North American Group Inc | 1 | $104 |
| Thea Pharma Inc. | 1 | $91 |
| Novartis | 2 | $45 |
| Harrow Eye, LLC | 2 | $42 |
| Sight Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$6,851
- Ortho-K Contact Lens$2,316
- AIR OPTIX$938
- Acuvue$928
- VUITY$875
- Clariti Contact Lens$825
- RXSIGHT CONTACT LENS$571
- RXSIGHT INJECTOR HANDPIECE$571
- LIGHT ADJUSTABLE LENS (LAL)$571
- RXSIGHT INJECTOR CARTRIDGE$571
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$571
- Non-Product Brand Specific$240
- XIIDRA$229
- Paragon CRT$167
- CE-marked KXLA system$134
- MIEBO$125
- TEPEZZA$124
- EYSUVIS$123
- CEQUA$122
- VYZULTA$120
How this compares
$20,346 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $17,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $1,105 | $17,39014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.
Other optometrist in Chicago
- Pamela LoweChicago$447K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Jennifer HarthanChicago$84K
- Neil HodurChicago$67K
- James SementilliChicago$25K
- Lindsay SicksChicago$23K
- Emma LoyfmanChicago$23K
- Vincent BrandysChicago$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.